U.S. markets close in 2 hours 43 minutes

Evogene Ltd. (EVGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.8900-0.0400 (-1.37%)
As of 1:07PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close2.9300
Open2.9100
Bid2.8700 x 2200
Ask2.9000 x 800
Day's Range2.8210 - 2.9300
52 Week Range0.7500 - 5.3000
Volume190,979
Avg. Volume1,076,413
Market Cap95.21M
Beta (5Y Monthly)0.32
PE Ratio (TTM)N/A
EPS (TTM)-0.8180
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    Evogene Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Evogene Ltd.

  • Evogene Reports Third Quarter 2020 Financial Results
    PR Newswire

    Evogene Reports Third Quarter 2020 Financial Results

    Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across several market segments, announced today its financial results for the third quarter ended September 30, 2020.

  • Canonic Received Approval for Propagation of Medical Cannabis from the Israel Medical Cannabis Agency
    PR Newswire

    Canonic Received Approval for Propagation of Medical Cannabis from the Israel Medical Cannabis Agency

    Canonic, a wholly owned subsidiary of Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN) focused on the development of medical cannabis products, announces today receiving an IMC-GAP approval from the Israel Medical Cannabis Agency for the commercial operation of its propagation farm. This approval will allow Canonic to proceed with the execution of its commercialization plan of medical cannabis products.